Le site du DES d'oncologie de Toulouse

Digestif

16 articles et aucun document

Articles
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Digestif - Publié le 14/05/2020 par Ilfad Blazevic

BACKGROUND

Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment... lire la suite


Neoadjuvant Short-Course Radiation Therapy for Rectal Cancer: Trends and Controversies
Digestif - Publié le 14/05/2020 par Ilfad Blazevic

Purpose of Review For patients with locally advanced rectal cancer, neoadjuvant hypofractionated short-course radiation remains an underutilized regimen in the USA. We review the current clinical lit... lire la suite


Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Digestif - Publié le 14/05/2020 par Ilfad Blazevic

BACKGROUND

Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, sinc... lire la suite


Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Digestif - Publié le 14/05/2020 par Ilfad Blazevic

BACKGROUND

A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a monoclonal antibody against vascular endothelial growth factor), is standard first-line treatmen... lire la suite


Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Digestif - Publié le 14/05/2020 par Ilfad Blazevic

Background

No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved standard therapies, but many patients maintain a good perform... lire la suite


Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Digestif - Publié le 14/05/2020 par Ilfad Blazevic

BACKGROUND

Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy.... lire la suite


RTOG 98-11 canal anal
Digestif - Publié le 06/05/2019 par Emily Alouani

... lire la suite


Etude CRITICS
Digestif - Publié le 02/05/2019 par Emily Alouani

... lire la suite


Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Digestif - Publié le 02/05/2019 par Emily Alouani

... lire la suite


Etude SHARP
Digestif - Publié le 02/05/2019 par Emily Alouani

... lire la suite


Etude Reflect
Digestif - Publié le 02/05/2019 par Emily Alouani

... lire la suite


Etude Keynote 061
Digestif - Publié le 02/05/2019 par Emily Alouani

... lire la suite


Etude ATTRACTION 2
Digestif - Publié le 02/05/2019 par Emily Alouani

... lire la suite


Etude FLOT
Digestif - Publié le 02/05/2019 par Emily Alouani

... lire la suite


Etude Celestial
Digestif - Publié le 02/05/2019 par Emily Alouani

... lire la suite


ACT II
Digestif - Publié le 02/05/2019 par Emily Alouani

... lire la suite